Reports › TER › 10-Q FY2025

SEC filings, compared

What changed in Teradyne,'s 10-Q for the quarter ended September 28, 2025

Compared with the 10-Q for the quarter ended September 29, 2024. Part I, Item 2 and Part II, Item 1A analysed; every summary checked against the quoted filing text.

Registrant: TERADYNE, INC · TER
This filing: 0001193125-25-258477 ↗ · filed Oct 30, 2025
Compared with: 0000950170-24-119923 ↗ · filed Nov 1, 2024
Processed: Sep 20, 2026 UTC · parser-v5 · classify-v4 · select-v1

Research tool. Describes what filings say. Not investment advice. Verify independently. Read the cited paragraph before relying on it.

How a report is made

45 material changes among 74 changed paragraphs

15 shown by default across the three sections below; each section's "Show all" reaches the rest, in filing order.

Numbers from XBRL

Each figure is the one the filing itself tagged, taken from the filing that reported it. Not written by a model.

Concept	FY2025	FY2024	Change (our arithmetic)
Revenueus-gaap:Revenues	769,210,000USD · Jun 30, 2025 to Sep 28, 2025	737,298,000USD · Jul 1, 2024 to Sep 29, 2024	+31,912,000+4.3%
Net income or lossus-gaap:NetIncomeLoss	119,558,000USD · Jun 30, 2025 to Sep 28, 2025	145,649,000USD · Jul 1, 2024 to Sep 29, 2024	−26,091,000−17.9%
Cash and cash equivalentsus-gaap:CashAndCashEquivalentsAtCarryingValue	272,700,000USD · at Sep 28, 2025	510,036,000USD · at Sep 29, 2024	−237,336,000−46.5%
Net cash from operating activitiesus-gaap:NetCashProvidedByUsedInOperatingActivities	392,776,000USD · Jan 1, 2025 to Sep 28, 2025	389,619,000USD · Jan 1, 2024 to Sep 29, 2024	+3,157,000+0.8%

Values as tagged in the filing's inline XBRL, resolved by accession rather than by period matching. When a value is not tagged, we show that instead of estimating it. FY2025: 0001193125-25-258477 · FY2024: 0000950170-24-119923

What the company says for the first time

Paragraphs with no counterpart in the prior filing.

6 material additions

Part I, Item 2 · MD&A

6 of 6 shown · In filing order, too few to rank

01AddedPart I, Item 2 › Overview

Summary · quote-checked

Added disclosure of Teradyne’s acquisition of Infineon’s automated test equipment technology and development team for 17.6 million Euros.

The paragraph introduces a new acquisition, purchase price, acquired resources, customer relationship, and segment classification, changing disclosed transactions and obligations.

Filing text · FY2024 10-Q · filed Nov 1, 2024

No corresponding language in the FY2024 10-Q.

Filing text · FY2025 10-Q · filed Oct 30, 2025

[added] On January 31, 2025, we acquired Infineon Technologies AG's ("Infineon") automated test equipment technology and associated development team ("AET") based in Regensburg, Germany for a total purchase price of 17.6 million Euros, equivalent to $18.3 million. AET adds resources and expertise to our company and strengthens the relationship between Teradyne and this key customer. AET is included in our Semiconductor Test segment.

Cite this change

"On January 31, 2025, we acquired Infineon Technologies AG's ("Infineon") automated test equipment technology and associated development team ("AET") based in Regensburg, Germany for a total purchase price of 17.6 million Euros, equivalent to $18.3 million."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

02AddedPart I, Item 2 › Overview

Summary · quote-checked

Added disclosure describing the capital allocation plan, acquisitions completed, and cash returned to shareholders during the first nine months of 2025.

The new paragraph adds substantive information about investment priorities, completed acquisitions, share repurchases, and dividend payments, including a quantified shareholder return.

Filing text · FY2024 10-Q · filed Nov 1, 2024

No corresponding language in the FY2024 10-Q.

Filing text · FY2025 10-Q · filed Oct 30, 2025

[added] Our capital allocation plan will continue to be balanced between investing in organic and inorganic growth and returning cash to shareholders through share repurchases and dividends. During the first nine months of 2025 we completed the acquisitions of Quantifi and AET and additionally, we returned $576.3 million to shareholders through $518.7 million of share buybacks and $57.6 million of dividend payments.

Cite this change

"Our capital allocation plan will continue to be balanced between investing in organic and inorganic growth and returning cash to shareholders through share repurchases and dividends. During the first nine months of 2025 we completed the acquisitions of Quantifi and AET and additionally, we returned $576.3 million to shareholders through $518.7 million of share buybacks and $57.6 million of dividend payments."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

03AddedPart I, Item 2 › Overview

Summary · quote-checked

Added disclosure of the OBBBA, its corporate tax-law changes, current financial statement impact, and Teradyne’s ongoing evaluation.

The paragraph introduces a newly enacted law, specific tax provisions, an assessment of financial statement impact, and a continuing obligation to evaluate guidance.

Filing text · FY2024 10-Q · filed Nov 1, 2024

No corresponding language in the FY2024 10-Q.

Filing text · FY2025 10-Q · filed Oct 30, 2025

[added] On July 4, 2025, H.R. 1, commonly referred to as the "One Big Beautiful Bill Act" ("OBBBA"), was signed into law, enacting significant changes to U.S. corporate tax law. The OBBBA modified and made permanent several provisions of the Tax Cuts and Jobs Act, including reductions in scheduled increases for the rate of taxation of foreign income, immediate deductibility of U.S. research and development expenses, and reinstatement of 100% bonus depreciation for qualified property. As of September 28, 2025, the condensed consolidated financial statements were not materially impacted by the OBBBA. Teradyne continues to evaluate the provisions of the OBBBA and will incorporate any necessary adjustments as further guidance becomes available.

Cite this change

"On July 4, 2025, H.R. 1, commonly referred to as the "One Big Beautiful Bill Act" ("OBBBA"), was signed into law, enacting significant changes to U.S. corporate tax law. The OBBBA modified and made permanent several provisions of the Tax Cuts and Jobs Act, including reductions in scheduled increases for the rate of taxation of foreign income, immediate deductibility of U.S. research and development expenses, and reinstatement of 100% bonus depreciation for qualified property. As of September 28, 2025, the condensed consolidated financial statements were not materially impacted by the OBBBA. Teradyne continues to evaluate the provisions of the OBBBA and will incorporate any necessary adjustments as further guidance becomes available."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

04AddedPart I, Item 2 › Overview

Summary · quote-checked

Added disclosure that trade restrictions limit competitiveness and that tariffs and evolving trade policies could affect operations, costs, supply chain, or market access.

The new paragraph introduces substantive disclosures about current restrictions, tariffs, export controls, regulatory measures, and their potential business effects.

Filing text · FY2024 10-Q · filed Nov 1, 2024

No corresponding language in the FY2024 10-Q.

Filing text · FY2025 10-Q · filed Oct 30, 2025

[added] While it is difficult to quantify the exact impact, current trade restrictions are limiting our ability to be competitive particularly in certain markets, where other companies are not subjected to the same restrictions. Current tariffs have not had a material impact on our business operations or financial results, however, the global trade environment remains dynamic and subject to change. We continue to monitor developments in international trade policy, including potential changes to tariffs, further export controls, and other regulatory measures that could affect our supply chain, cost structure, or market access.

Cite this change

"While it is difficult to quantify the exact impact, current trade restrictions are limiting our ability to be competitive particularly in certain markets, where other companies are not subjected to the same restrictions. Current tariffs have not had a material impact on our business operations or financial results, however, the global trade environment remains dynamic and subject to change. We continue to monitor developments in international trade policy, including potential changes to tariffs, further export controls, and other regulatory measures that could affect our supply chain, cost structure, or market access."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

05AddedPart I, Item 2 › Third Quarter 2025 Compared to Third Quarter 2024

Summary · quote-checked

Adds an explanation that lower current-period cash balances primarily drove the decrease in interest income.

The new MD&A sentence introduces a specific driver of a reported decrease, substantively expanding the company’s explanation of results.

Filing text · FY2024 10-Q · filed Nov 1, 2024

No corresponding language in the FY2024 10-Q.

Filing text · FY2025 10-Q · filed Oct 30, 2025

[added] The decrease in interest income was driven primarily by lower cash balances in the current period.

Cite this change

"The decrease in interest income was driven primarily by lower cash balances in the current period."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

06AddedPart I, Item 2 › Recently Issued Accounting Pronouncements

Summary · quote-checked

Added disclosure of a new FASB standard providing a practical expedient for estimating expected credit losses on certain receivables and contract assets.

The new paragraph identifies a recently issued accounting standard, its effective date and adoption method, and the company’s evaluation of its expected financial statement impact.

Filing text · FY2024 10-Q · filed Nov 1, 2024

No corresponding language in the FY2024 10-Q.

Filing text · FY2025 10-Q · filed Oct 30, 2025

[added] In July 2025, the FASB issued ASU 2025-05 - "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets", which introduces a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606. The practical expedient permits all entities to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. This standard is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The amendments in this update should be applied on a prospective basis, but retrospective application is permitted. We are currently evaluating the impact of this new standard and do not expect a material impact on the financial statements and related disclosures.

Cite this change

"In July 2025, the FASB issued ASU 2025-05 - "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets", which introduces a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

What the company no longer says

Paragraphs of the prior filing that this filing dropped. Only last year's text can show these.

4 material removals

Part I, Item 2 · MD&A

4 of 4 shown · In filing order, too few to rank

01RemovedPart I, Item 2 › Overview

Summary · quote-checked

Removed disclosure describing the Robotics segment, its market adoption dependency, and its expected full-year growth drivers.

The removed paragraph disclosed a business dependency and management outlook, so its absence changes substantive MD&A content rather than merely wording or formatting.

Filing text · FY2024 10-Q · filed Nov 1, 2024

[removed] Our Robotics segment consists of Universal Robots A/S ("UR"), a leading supplier of collaborative robotic arms, and Mobile Industrial Robots A/S ("MiR"), a leading maker of AMRs for industrial automation. The market for our Robotics segment products is dependent on the adoption of new automation technologies by large manufacturers as well as small and medium enterprises ("SMEs") throughout the world. Robotics results in the third quarter of 2024 were in line with our revenue forecast, putting us in position for full year growth due to new product offerings and expansion of our Original Equipment Manufacturer ("OEM") and large account channels, along with increasing recurring revenue through new service and software offerings.

Filing text · FY2025 10-Q · filed Oct 30, 2025

No corresponding language in the FY2025 10-Q.

Cite this change

"Our Robotics segment consists of Universal Robots A/S ("UR"), a leading supplier of collaborative robotic arms, and Mobile Industrial Robots A/S ("MiR"), a leading maker of AMRs for industrial automation. The market for our Robotics segment products is dependent on the adoption of new automation technologies by large manufacturers as well as small and medium enterprises ("SMEs") throughout the world. Robotics results in the third quarter of 2024 were in line with our revenue forecast, putting us in position for full year growth due to new product offerings and expansion of our Original Equipment Manufacturer ("OEM") and large account channels, along with increasing recurring revenue through new service and software offerings."

Teradyne,, Form 10-Q for FY2024, Part I, Item 2, accession 0000950170-24-119923, filed 1 November 2024.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000095017024119923/ter-20240929.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

02RemovedPart I, Item 2 › Overview

Summary · quote-checked

The current filing removes disclosure describing the company’s strategy, increased engineering and go-to-market spending, and capital allocation priorities.

The removed paragraph contains substantive statements about market-share strategy, investment commitments, acquisitions, repurchases, dividends, and capital allocation, rather than recurring wording or boilerplate.

Filing text · FY2024 10-Q · filed Nov 1, 2024

[removed] Our corporate strategy continues to focus on profitably gaining market share in our test businesses through the introduction of differentiated products that target expanding segments and accelerating growth through continued investment in our Robotics businesses. We have strategically increased engineering and go-to-market spending, primarily in Semiconductor Test and Integrated System Test, in order to support market share gains. We plan to execute on our strategy while balancing capital allocations between returning capital to our shareholders through stock repurchases and dividends and using capital for opportunistic accretive acquisitions.

Filing text · FY2025 10-Q · filed Oct 30, 2025

No corresponding language in the FY2025 10-Q.

Cite this change

"Our corporate strategy continues to focus on profitably gaining market share in our test businesses through the introduction of differentiated products that target expanding segments and accelerating growth through continued investment in our Robotics businesses. We have strategically increased engineering and go-to-market spending, primarily in Semiconductor Test and Integrated System Test, in order to support market share gains. We plan to execute on our strategy while balancing capital allocations between returning capital to our shareholders through stock repurchases and dividends and using capital for opportunistic accretive acquisitions."

Teradyne,, Form 10-Q for FY2024, Part I, Item 2, accession 0000950170-24-119923, filed 1 November 2024.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000095017024119923/ter-20240929.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

03RemovedPart I, Item 2 › Third Quarter 2024 Compared to Third Quarter 2023

Summary · quote-checked

Removed the explanation that Other (income) expense increased by $8.3 million, primarily due to foreign exchange and actuarial gains.

The removed MD&A paragraph disclosed a reported change, its amount, and stated drivers; this is substantive information rather than a date, formatting, or recurring-list update.

Filing text · FY2024 10-Q · filed Nov 1, 2024

~~[removed] Other (income) expense reflects a net increase of $8.3 million primarily due to foreign exchange and actuarial gains.~~

Filing text · FY2025 10-Q · filed Oct 30, 2025

No corresponding language in the FY2025 10-Q.

Cite this change

"Other (income) expense reflects a net increase of $8.3 million primarily due to foreign exchange and actuarial gains."

Teradyne,, Form 10-Q for FY2024, Part I, Item 2, accession 0000950170-24-119923, filed 1 November 2024.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000095017024119923/ter-20240929.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

04RemovedPart I, Item 2 › Liquidity and Capital Resources

Summary · quote-checked

Removed disclosure that the Board approved a new repurchase program for up to $2.0 billion of common stock.

The removed paragraph disclosed a share-repurchase authorization and its maximum amount, changing the stated capital-allocation commitment.

Filing text · FY2024 10-Q · filed Nov 1, 2024

~~[removed] In January 2023, our Board of Directors cancelled the 2021 repurchase program and approved a new repurchase program for up to $2.0 billion of common stock.~~

Filing text · FY2025 10-Q · filed Oct 30, 2025

No corresponding language in the FY2025 10-Q.

Cite this change

"In January 2023, our Board of Directors cancelled the 2021 repurchase program and approved a new repurchase program for up to $2.0 billion of common stock."

Teradyne,, Form 10-Q for FY2024, Part I, Item 2, accession 0000950170-24-119923, filed 1 November 2024.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000095017024119923/ter-20240929.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

What the company says differently

Paragraphs that changed between the two filings, shown as a word diff.

35 material changes

Part I, Item 2 · MD&A

5 of 35 shown · Ordered by the model, quote-checked

01ChangedPart I, Item 2 › Liquidity and Capital Resources

Summary · quote-checked

The disclosure replaces repaid 2024 borrowing for a Technoprobe acquisition with 2025 borrowing for capital allocation and $250.0 million outstanding.

Borrowing timing, purpose, amount, and outstanding balance changed, altering the stated liquidity and credit-facility exposure.

Why the model ranked it here

The company now reports new borrowing for capital allocation with debt remaining outstanding, materially changing its credit-facility exposure and liquidity profile.

Filing text · FY2024 10-Q · filed Nov 1, 2024

On May 1, 2020, we entered into a credit agreement providing a three-year, senior secured revolving credit facility of $400.0 million. On December 10, 2021, the ~~[removed] credit agreement~~ was amended to extend the senior secured revolving credit facility to December 10, 2026. On October 5, 2022, the ~~[removed] credit agreement~~ was amended to increase the amount of the credit facility to $750.0 million from $400.0 million. On November 7, 2023, the Credit Agreement was amended to allow for the purchase of the shares of Technoprobe. On [removed] May 16, 2024, we borrowed $185.0 million under the credit agreement to fund the acquisition of 10% of the issued and outstanding shares of Technoprobe. We fully repaid our borrowings on the revolving credit facility prior to September 29, 2024. As of ~~[removed] November 1, 2024, there are no outstanding borrowings under the credit facility.~~

Filing text · FY2025 10-Q · filed Oct 30, 2025

On May 1, 2020, we entered into a credit agreement [added] (the "Credit Agreement") providing a three-year, senior secured revolving credit facility of $400.0 million. On December 10, 2021, the [added] Credit Agreement was amended to extend the senior secured revolving credit facility to December 10, 2026. On October 5, 2022, the [added] Credit Agreement was amended to increase the amount of the credit facility to $750.0 million from $400.0 million. On November 7, 2023, the Credit Agreement was amended to allow for the purchase of the shares of Technoprobe. On [added] September 4, 2025, and September 19, 2025, we borrowed a combined $200.0 million under the Credit Agreement to fund out capital allocation strategy. As of [added] October 30, 2025, there is $250.0 million outstanding from the Credit Facility.

Cite this change

"On September 4, 2025, and September 19, 2025, we borrowed a combined $200.0 million under the Credit Agreement to fund out capital allocation strategy. As of October 30, 2025, there is $250.0 million outstanding from the Credit Facility."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

02Figures updatedPart I, Item 2 › Liquidity and Capital Resources

Summary · quote-checked

Cash, cash equivalents and marketable securities decreased by a larger amount to a lower ending balance in the current period.

The changed figures describe remaining liquidity and its period decrease, yielding a substantively different liquidity position rather than merely rolling forward the reporting period.

Why the model ranked it here

The lower balance of cash and marketable securities changes the company’s disclosed liquidity position and available funding cushion.

Filing text · FY2024 10-Q · filed Nov 1, 2024

Our cash, cash equivalents and marketable securities balances decreased by ~~[removed] $259.5~~ million in the nine months ended September ~~[removed] 29, 2024, to $677.6~~ million.

Filing text · FY2025 10-Q · filed Oct 30, 2025

Our cash, cash equivalents and marketable securities balances decreased by [added] $296.4 million in the nine months ended September [added] 28, 2025, to $427.4 million.

Cite this change

"Our cash, cash equivalents and marketable securities balances decreased by $296.4 million in the nine months ended September 28, 2025, to $427.4 million."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

03ChangedPart I, Item 2 › Overview

Summary · quote-checked

The overview replaces a Technoprobe partnership, investment and business sale with Quantifi’s acquisition and planned integration into existing platforms.

The disclosure changes from a strategic partnership and divestiture transaction to a new acquisition, purchase price, segment assignment and intended technology integration.

Why the model ranked it here

The company replaced a prior strategic investment and divestiture with an acquisition intended to integrate new technology into its existing platforms.

Filing text · FY2024 10-Q · filed Nov 1, 2024

On ~~[removed] November 7, 2023, we and Technoprobe S.p.A, ("Technoprobe"),~~ a leader in [removed] the design and production of probe cards, announced the establishment of a strategic partnership that will seek to accelerate growth for both companies and enable higher performance semiconductor test interfaces for customers worldwide. As part of the partnership, on May 27, 2024, we made an investment of $524.1 million in exchange for 10% of the issued and outstanding shares of Technoprobe, and we sold our Device Interface Solutions ("DIS") business to Technoprobe in exchange for $85.0 million, net of cash and cash equivalents sold, and a customary working capital adjustment.

Filing text · FY2025 10-Q · filed Oct 30, 2025

On [added] May 31, 2025, we acquired privately held Quantifi Photonics ("Quantifi"), a leader in [added] PIC test solutions for a total purchase price of approximately $127.2 million. This acquisition enables the delivery of scalable PIC test solutions and is included in our Product Test segment. Over time, we also intend to leverage the engineering expertise and technology to enhance functionality and create additional differentiation in our Semiconductor Test business, specifically with integration into our UltraFlexPlus platform.

Cite this change

"On May 31, 2025, we acquired privately held Quantifi Photonics ("Quantifi"), a leader in PIC test solutions for a total purchase price of approximately $127.2 million."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

04ChangedPart I, Item 2 › Overview

Summary · quote-checked

The outlook shifts from compute- and memory-led Semiconductor Test demand with mobility weakness to AI and data-center-driven growth, investment, and added Robotics discussion.

The stated demand drivers, forecast horizon, investment plans, and segment outlook changed substantively; mobility weakness and anticipated recovery were replaced by AI expansion and Robotics strategy.

Why the model ranked it here

The stated growth outlook now centers on artificial intelligence and data-center demand rather than the prior compute, memory, and mobility framing.

Filing text · FY2024 10-Q · filed Nov 1, 2024

~~[removed] In the third quarter of 2024, we saw strength in Semiconductor Test performance driven in System-on-a-chip by compute and in memory by DRAM and high bandwidth memory.~~ We expect ~~[removed] compute and memory~~ to continue ~~[removed] to drive meaningful demand in the fourth quarter of 2024, helping to offset weakness~~ in the ~~[removed] mobility test market. We anticipate an eventual upturn in mobility at some point in 2025.~~

Filing text · FY2025 10-Q · filed Oct 30, 2025

[added] Artificial Intelligence applications and data center power demand drove strong third quarter performance with our customers accelerating development and ramping production for a wide range of devices. We expect [added] this acceleration to continue [added] and even expand into the fourth quarter and into 2026 and are currently investing in sales, engineering, and support to pursue these, and additional, market opportunities in Semiconductor Test. Robotics revenue in the third quarter was flat with second quarter sales due to ongoing business environment challenges. Our focus in the [added] Robotics segment remains on operating expense management and our channel transformation strategy as we transition toward serving large direct customers and building a Robotics organization that can grow profitably over the mid-term.

Cite this change

"Artificial Intelligence applications and data center power demand drove strong third quarter performance with our customers accelerating development and ramping production for a wide range of devices."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

05ChangedPart I, Item 2 › Nine Months 2025 Compared to Nine Months 2024

Summary · quote-checked

The disclosure changed from prior-period restructuring and contract termination charges to current severance, employee impacts, payments, expected timing, and acquisition, divestiture, and lease termination expenses.

The paragraph adds and removes substantive charges, restructuring scope, affected employees, cash payments, expected payment timing, and expense categories; these changes alter disclosed obligations and events.

Why the model ranked it here

The filing adds substantial restructuring-related severance payments and timing obligations while also introducing acquisition, divestiture, and lease-termination costs.

Filing text · FY2024 10-Q · filed Nov 1, 2024

During the ~~[removed] three~~ months ended ~~[removed] October 1, 2023,~~ we recorded ~~[removed] restructuring and other charges primarily~~ related to ~~[removed] $4.7~~ million of ~~[removed] severance charges~~ related to [removed] headcount reductions of 94 people, principally in Semiconductor Test and Robotics, which included charges related to a voluntary early retirement program for employees meeting certain conditions, and a $1.5 million ~~[removed] contract termination charge.~~

Filing text · FY2025 10-Q · filed Oct 30, 2025

During the [added] nine months ended [added] September 28, 2025, we recorded [added] $18.5 million of severance charges, $13.5 million of which is related to [added] the Robotics restructuring which impacted approximately 150 employees, $2.2 million of [added] which is related to [added] Product Test and $1.4 million of which is related to Semiconductor Test. During the nine months ended September 28, 2025, we made $9.2 million of Robotics severance payments. We expect all Robotics severance payments to be made prior to the end of the third quarter of 2026. Additionally, we recorded $2.0 million of acquisition and divestiture expenses related primarily to the Quantifi Acquisition and $1.5 million [added] of charges related to lease terminations.

Cite this change

"During the nine months ended September 28, 2025, we recorded $18.5 million of severance charges, $13.5 million of which is related to the Robotics restructuring which impacted approximately 150 employees, $2.2 million of which is related to Product Test and $1.4 million of which is related to Semiconductor Test. During the nine months ended September 28, 2025, we made $9.2 million of Robotics severance payments. We expect all Robotics severance payments to be made prior to the end of the third quarter of 2026. Additionally, we recorded $2.0 million of acquisition and divestiture expenses related primarily to the Quantifi Acquisition and $1.5 million of charges related to lease terminations."

Teradyne,, Form 10-Q for FY2025, Part I, Item 2, accession 0001193125-25-258477, filed 30 October 2025.

Filing: https://www.sec.gov/Archives/edgar/data/97210/000119312525258477/ter-20250928.htm

Comparison: https://yearover.com/reports/ter/0001193125-25-258477?ref=quote

Show all 35 in Part I, Item 2 (30 more, in filing order)

What the company reported as changed this quarter

We have not parsed the annual report this quarter's risk factors refers to, so we cannot tell whether it restates the section or reports changes to it. Nothing is compared until we can.

Part II, Item 1A · Risk Factors

Get this when TER files next

At most one email a day, and only when a company we cover files. Over the last twelve months that averaged about 5 days a month, unevenly: 12 in the busiest month and 1 in the quietest. You confirm by email first; nothing is sent until you do.